NCT06601517View on ClinicalTrials.gov

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

April 30, 2025

Conditions
Healthy Adult SubjectOverweight Subject
Interventions
DRUG

Repaglinide

Single dose; Administered orally

DRUG

Atorvastatin

Single dose; Administered orally

DRUG

Digoxin

Single dose; Administered orally

DRUG

Rosuvastatin

Single dose; Administered orally

DRUG

HDM1002

Administered orally

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06601517 - A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. | Biotech Hunter | Biotech Hunter